Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Drugmakers lost an attempt April 13 to move a battle with buyers of blockbuster drugs Effexor XR and Lipitor into what would likely be a friendlier court ( In re: Effexor XR Antitrust Litig. , 3d Cir., 15-01342, 4/13/17 ).
The U.S. Court of Appeals for the Third Circuit rejected arguments from Wyeth Pharmaceuticals, Pfizer Inc., Ranbaxy Inc., Teva Pharmaceuticals USA Inc. and other drugmakers that claims they illegally delayed generic competition for Effexor and Lipitor belong in the U.S. Court of Appeals for the Federal Circuit, which has exclusive jurisdiction of cases based on patent law.
The court that hears the case will impact the developing law around “pay for delay” agreements between generic and brand drugmakers settling patent disputes. The exact legal details of a “pay for delay” settlement are still in flux after the Federal Trade Commission convinced the Supreme Court in FTC v. Actavis that such payments violate antitrust law.
Had the defendants been successful in moving the case to the specialty federal circuit, “the post-Actavis law could have developed in this patent-friendly court,” said Rutgers Law School Professor Michael Carrier.
The Third Circuit said the plaintiffs’ claims that the drugmakers engaged in illegal reverse payments and lied to the U.S. Patent Office didn’t arise under patent law, so they don’t belong before the Federal Circuit. The court said that, based on that decision, the same panel of Circuit Judges D. Michael Fisher, Thomas L. Ambro and D. Brooks Smith will hear the merits of the plaintiffs appeals.
For purposes of this opinion, the court combined two appeals: one in In re Lipitor Antitrust Litigation, Nos. 14-4202 through -4206 and 14-4602, and In re Effexor XR Antitrust Litigation, 14-01342. Each consists of several cases being litigated together.
In both appeals, direct and indirect buyers of each drug alleged that the drug companies conspired to delay generic entry with a reverse-payment settlement agreement and also engaged in various unfair practices before the Patent Office and/or the Food and Drug Administration.
In both cases, the lower court dismissed the plaintiffs’ reverse payment claims. The Federal Trade Commission and a group of professors, including Carrier, have filed briefs in the Effexor case supporting some of the plaintiffs’ arguments on the merits. The same group of professors has also weighed in on the plaintiffs’ behalf in the Lipitor case.
The Pharmaceutical Research and Manufacturers of America and the Generic Pharmaceutical Association—now the Association for Accessible Medicines— filed briefs supporting the drugmakers in both cases.
The court remanded one of the individual Lipitor cases for clarification on whether the district court had jurisdiction of the case when it entered judgment. If the district court lacked jurisdiction, the appellate court likewise wouldn’t be able to review the case.
To contact the reporter on this story: Eleanor Tyler in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Fawn Johnson at email@example.com
The court's opinion is at http://src.bna.com/nWG.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)